VANCOUVER, BC / ACCESSWIRE / September 6, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FSE: 2VP) ("VRT" or the "Company"), an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that 1,000,000 stock options have been issued; 200,000 each to its two new directors; Dr. Don Carlow and Mr. Matthew Hamilton; as well as 300,000 to the Company's Chief Financial Officer, 100,000 to the Company's President, and 200,000 to one additional consultant. The options will be vested immediately and have an exercise price of $0.32. The options will expire, if unexercised, in five years from date of issue.
About VERITAS Pharma Inc.
Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a 'lean and mean' approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas's scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.
On behalf of the Board of Directors
Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
SOURCE: Veritas Pharma Inc.